SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Systematic Review and Meta-Analysis - Data and Code

Data, code, and supplementary materials for the systematic review and meta-analysis: "Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis with Trial Sequential Analysis" MAIN FINDINGS:- Primary outcome (CV death or HF hospitalization): HR 0.80 (95% CI 0.73-0.87)- Trial Sequential Analysis: Conclusive evidence (146% of required information size)- NNT: ~58 patients per year- 2 dedicated HFpEF trials included (DELIVER, EMPEROR-Preserved; n=12,251) CONTENTS:- Extracted study data (CSV)- Complete R analysis scripts- All manuscript and supplementary figures (17 PDFs)- RMarkdown source files- Data dictionary REGISTRATION: PROSPERO CRD420251167908 Keywords: SGLT2 inhibitors, heart failure, preserved ejection fraction, HFpEF, meta-analysis, trial sequential analysis, dapagliflozin, empagliflozin

Keywords

Heart Failure, meta-analysis, systematic review, Meta-Analysis as Topic, HFpEF, SGLT2 inhibitors, preserved ejection fraction, trial sequential analysis, Systematic Reviews as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average

Found an issue? Give us feedback

0

Average